PMID- 35069811
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 1759-720X (Print)
IS  - 1759-7218 (Electronic)
IS  - 1759-720X (Linking)
VI  - 14
DP  - 2022
TI  - Based on minimal clinically important difference values, a moderate dose of 
      tanezumab may be a better option for treating hip or knee osteoarthritis: a 
      meta-analysis of randomized controlled trials.
PG  - 1759720X211067639
LID - 10.1177/1759720X211067639 [doi]
LID - 1759720X211067639
AB  - BACKGROUND: Tanezumab is a nerve growth factor monoclonal antibody that may 
      regulate pain in hip or knee osteoarthritis (OA). This meta-analysis was 
      performed to evaluate the efficacy and safety of low and moderate doses of 
      tanezumab in treating hip or knee OA. METHODS: PubMed, EMBASE, the Cochrane 
      Library, and Web of Science were comprehensively searched for clinical trials 
      published before 1 May 2021. Patients were assessed via efficacy and safety 
      outcomes. RESULTS: Twelve randomized controlled trials including 6022 patients 
      were identified. Both low and moderate doses of tanezumab significantly improved 
      efficacy outcomes. However, only the point estimates (mean difference, MD) of 
      moderate-dose tanezumab significantly exceeded the minimal clinically important 
      differences (MCIDs). There were no significant differences in the incidence of 
      treatment-related adverse events (AEs), withdrawals due to AEs, serious AEs, and 
      total joint replacement between the tanezumab and placebo groups, whereas the 
      incidence of AEs was higher in the tanezumab group (relative risk, RR = 1.10; 95% 
      confidence interval, 95% CI = 1.04-1.17). The incidence of rapidly progressive OA 
      was significantly higher in the combined low- and moderate-dose tanezumab groups 
      than in the placebo group (RR = 5.01; 95% CI = 1.17-21.33). Furthermore, both low 
      and moderate doses of tanezumab significantly increased the incidence of abnormal 
      peripheral sensation (RR = 1.99, 95% CI = 1.21-3.28; RR = 2.64, 95% 
      CI = 1.91-3.67, respectively). Compared with nonsteroidal anti-inflammatory drugs 
      (NSAIDs) and opioids, tanezumab showed significantly improved efficacy outcomes 
      (p < 0.05). However, the point estimates (MD) of tanezumab were not greater than 
      the MCID. Pooled analysis showed no significant differences between tanezumab and 
      NSAIDs and opioids in safety outcomes (p > 0.05). CONCLUSION: Tanezumab is 
      efficacious in patients with hip or knee OA. Tanezumab is relatively well 
      tolerated and safe but increases the incidence of AEs and reversible abnormal 
      peripheral sensation. Additional studies on the occurrence of rapidly progressive 
      OA are needed. A moderate dose of tanezumab may maximize the benefits for hip or 
      knee OA.
CI  - (c) The Author(s), 2022.
FAU - Zhao, Di
AU  - Zhao D
AD  - The Second Clinical School of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Luo, Ming-Hui
AU  - Luo MH
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
FAU - Pan, Jian-Ke
AU  - Pan JK
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
FAU - Zeng, Ling-Feng
AU  - Zeng LF
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
FAU - Liang, Gui-Hong
AU  - Liang GH
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
FAU - Han, Yan-Hong
AU  - Han YH
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
FAU - Liu, Jun
AU  - Liu J
AUID- ORCID: 0000-0002-2440-4064
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou 510120, China.
FAU - Yang, Wei-Yi
AU  - Yang WY
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou 510120, China.
LA  - eng
PT  - Address
DEP - 20220119
PL  - England
TA  - Ther Adv Musculoskelet Dis
JT  - Therapeutic advances in musculoskeletal disease
JID - 101517322
PMC - PMC8777347
OTO - NOTNLM
OT  - OA
OT  - anti-NGF antibody
OT  - meta-analysis
OT  - osteoarthritis
OT  - randomized controlled trials
OT  - tanezumab
COIS- Conflict of interest statement: The authors declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2022/01/25 06:00
MHDA- 2022/01/25 06:01
PMCR- 2022/01/19
CRDT- 2022/01/24 08:50
PHST- 2021/08/03 00:00 [received]
PHST- 2021/12/01 00:00 [accepted]
PHST- 2022/01/24 08:50 [entrez]
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/01/25 06:01 [medline]
PHST- 2022/01/19 00:00 [pmc-release]
AID - 10.1177_1759720X211067639 [pii]
AID - 10.1177/1759720X211067639 [doi]
PST - epublish
SO  - Ther Adv Musculoskelet Dis. 2022 Jan 19;14:1759720X211067639. doi: 
      10.1177/1759720X211067639. eCollection 2022.